ProCE Banner Activity

APPLY-PNH: Phase III Trial of Iptacopan Monotherapy in Patients With Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia With Anti-C5 Therapy

Slideset Download
Conference Coverage

In patients with paroxysmal nocturnal hemoglobinuria and residual anemia on stable anti‒complement 5 standard-of-care therapy, iptacopan monotherapy provided significant hematologic improvement vs continued standard-of-care treatment.

Released: December 17, 2022

Expiration: December 16, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen